Two terms remain unsettled. Coverage conflicts on the closing timeline: some outlets expect the deal to close before the end of 2026, while others say 2027. Coverage also conflicts on payment. TechBuzz describes a mix of cash and stock, but most other reports describe an all-cash deal. No regulators or legislation have been named in the coverage, and the filing details are not yet public.
The deal marks a clear move from wearables toward clinical care. It comes after Oura postponed an IPO of up to $2.2 billion on September 29, 2026, citing IPO market uncertainty. The company was valued at $11 billion after a $900 million late-stage round in October 2025, and it reported preliminary, unaudited revenue of $533 million for the quarter ended September 30, up 153% year over year. Analysts read the acquisition as a bet on AI-driven primary care at a time when Oura has delayed going public. Critics question whether giving members physician access turns Oura into a care-delivery business. Oura and Counsel point to survey data in which more than 90% of surveyed Oura members who use Counsel said their ring data helped them get better care, and Counsel's physicians average 4.6 out of 5. Attorneys advising health tech, payers, or employers should watch the closing timeline, the final payment structure, and whether any regulatory review follows for a wearable company that now delivers clinical services.